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Abstract
Background Overactive bladder (OAB) is often associ-
ated with a number of co-morbid medical conditions,
including diabetes mellitus. This may necessitate several
concomitant treatments, thus creating the potential for
drug–drug interactions (DDIs). Trospium is renally elimi-
nated, not metabolized via cytochrome P450; therefore,
cytochrome P450 DDIs are unlikely. However, coadmin-
istration with another renally eliminated drug (e.g., met-
formin) may theoretically result in a DDI.
Objective The objective of this study was to evaluate the
pharmacokinetics (plasma and urine) and safety/tolerability
of the coadministration of trospium chloride extended
release (XR) and metformin under steady-state conditions
in healthy male and female subjects.
Methods In a single-centre, randomized, open-label, two-
group, two-period study in healthy males and females aged
18–45 years, 44 subjects received oral metformin 500 mg
twice daily for 3.5 days during one period, and oral tros-
pium chloride XR 60 mg once daily for 10 days, followed
by trospium chloride XR 60 mg once daily for 4 days plus
metformin 500 mg twice daily for 3.5 days during the
other period. The two periods occurred in a crossover
fashion, separated by a 3-day washout period.
Results Trospium chloride XR coadministration did not
alter metformin steady-state pharmacokinetics. Metformin
coadministration reduced trospium steady-state maximum
plasma concentration (by 34 %) and area under the con-
centration–time curve from 0–24 hours (by 29 %). Neither
drug’s renal clearance was affected. No safety/tolerability
issues of concern were observed with coadministration.
Conclusion No dosage adjustment is necessary for met-
formin when coadministered with trospium chloride XR.
1 Introduction
Overactive bladder (OAB) is a common condition, affect-
ing an estimated 17 %–19 % of adults in the USA [1, 2].
OAB is associated with a number of co-morbid medical
conditions, including diabetes mellitus and obesity [3–6].
Co-morbid conditions may necessitate concurrent treat-
ment with any OAB therapies, allowing for the potential
for drug–drug interactions (DDIs).
The quaternary amine antimuscarinic trospium differs
from the tertiary amine antimuscarinics used to treat OAB
in that it is renally eliminated rather than metabolized by
the cytochrome P450 (CYP450) pathway; therefore, tros-
pium has a low propensity for DDIs with drugs metabo-
lized by CYP450 [7]. Of the dose absorbed (\10 %)
following oral administration, approximately 60 %–80 %
of the parent compound is excreted unchanged in the urine
[7–9]. Trospium has been hypothesized to undergo ester
hydrolysis with subsequent conjugation of benzylic acid to
form azoniaspironortropanol with glucuronic acid, which is
known to account for only approximately 7 %–10 % of
urinary excretion. The mean renal clearance for trospium is
approximately four times higher than the average glomer-
ular filtration rate, indicating that active tubular secretion is
a major route of elimination for trospium [7, 8]. Therefore,
concomitant administration of trospium chloride with
another renally excreted drug, particularly those that also
undergo tubular secretion, may result in a DDI if they
compete for the same transporter, e.g., organic cation
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transporters (OCTs). However, a pharmacokinetic study
indicated no DDI between trospium chloride and digoxin,
which is renally eliminated [10].
The biguanide oral antihyperglycaemic agent metformin
is indicated for the treatment of patients with type 2 dia-
betes mellitus, in whom use of the drug is associated with
improved glycaemic control and stable or slightly
decreased body weight [11]. Metformin may also be used
to reduce progression to type 2 diabetes in patients at risk
[12–15], and has been shown to promote weight loss in
patients with obesity [16–19]. Metformin was the sixth
most commonly prescribed medication in the USA in 2009
[20], and it is the most widely prescribed oral medication
for the treatment of diabetes [21]. Metformin is primarily
excreted unchanged in the urine, without hepatic metabo-
lism or biliary secretion [11]. The renal clearance of met-
formin is approximately 3.5 times greater than creatinine
clearance, indicating that tubular secretion is a major route
of elimination for the drug [7]. Approximately 90 % of the
absorbed metformin dose is eliminated renally within the
first 24 hours following oral administration [11]. No
metabolites have been identified following administration
of metformin to humans [11, 22].
Given that OAB is a common co-morbidity of diabetes,
metformin and trospium chloride are likely to be co-pre-
scribed and, since both drugs undergo renal excretion, there
is a potential for each drug to affect the systemic exposure
and/or half-life of the other drug. Human OCTs (hOCTs)
are involved in both the intestinal absorption and renal and/
or hepatic elimination of metformin (hOCT1,2) and tros-
pium (hOCT1,2,3), and could contribute to their active
tubular and hepatobiliary secretion [23, 24]. Consequently,
it is possible that transport of one or both of these agents
might be inhibited by the administration of the other agent,
thus affecting their absorption and/or elimination. There-
fore, the purpose of this study was to investigate the
pharmacokinetics, safety and tolerability of coadministra-
tion of trospium chloride extended release (XR) with
metformin under steady-state conditions.
2 Methods
This single-centre, randomized, open-label, two-period,
crossover study (Fig. 1) enrolled healthy male and female
subjects aged 18–45 years weighing within ±30 % of their
ideal body weight for height and frame size (according to
Metropolitan height and weight tables). Subjects were
required to be non-smokers (refraining from tobacco usage,
including smokeless tobacco, nicotine patches, etc., for
1 month prior to screening visit). In addition, subjects had
to abstain from caffeine-containing food and beverages for
24 hours prior to dosing, alcohol-containing food and
beverages for 48 hours prior to dosing, and Seville oranges
(e.g., orange marmalade), grapefruit or grapefruit juice for
7 days prior to dosing, and from all such products
throughout the study.
This crossover study was an AB?BA sequence
design with all subjects completing two crossover peri-
ods (Fig. 1). Due to the long half-life of trospium
chloride XR (consequently requiring a long drug wash-
out period), the sequence effect of trospium chloride XR
could not be determined because the combination
treatment is always administered after the trospium
chloride XR alone treatment. The protocol was designed
so that the washout time for the long-acting trospium
chloride XR formulation was kept to a reasonable length
of time while not appreciably altering the interpretation
of the DDI study. The study design was consistent with
US Food and Drug Administration guidance for long
half-life DDI studies.
Subjects received oral metformin (Glucophage; Bris-
tol-Myers Squibb, Princeton, NJ, USA) or oral trospium
chloride XR (Sanctura XR; Allergan, Inc., Irvine, CA,
USA) according to the study protocol (Fig. 1). Subjects
were instructed to take trospium chloride XR once daily at
7 am, on an empty stomach 1 hour before breakfast, and
metformin twice daily at 8 am and 6 pm with a standard-
ized meal (2,500 calories/day with 30 % fat). Overnight
fasting was required before the scheduled clinic attendance
on Days 4, 17 and 21 for Group A, and Days 10, 14 and 27
for Group B. The only concomitant medications permitted
during the study were hormonal contraceptives and para-
cetamol (acetaminophen) B2 g/day.
2.1 Pharmacokinetic Evaluation
For the measurement of plasma and urine concentrations of
trospium and metformin, serial blood and urine samples
were collected from each subject. Collection time points
for the metformin-alone treatment were pre-dose and 0.5,
0.75, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16 and 24 h post-dose for
plasma samples, and pre-dose and 0–4, 4–12 and 12–24 h
post-dose for pooled urine samples on Day 4 for Group A
and Day 27 for Group B. Collection time points for the
trospium chloride XR–alone treatment were pre-dose and
1, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 h post-dose for plasma
samples, and pre-dose and 0–4, 4–12 and 12–24 h post-
dose for pooled urine samples on Day 10 for Group B and
Day 17 for Group A. Collection time points following
coadministration of trospium chloride XR and metformin
were pre-trospium chloride XR dose and 1, 2, 3, 4, 5, 6, 8,
10, 12, 16, 24, 48, 72, 96, 120 and 144 h post-trospium
chloride XR dose for plasma samples, and pre-metformin
dose and 0–4, 4–12 and 12–24 h post-metformin dose for
pooled urine samples on Day 14 for Group B and Day 21
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for Group A. The final plasma pharmacokinetic sample was
collected on Day 34 at 312 h post-dose for Group A, and at
168 h post-dose for Group B.
Plasma and urine samples were analysed at Prevalere
Life Sciences, LLC (Whitesboro, NY, USA). Plasma and
urine trospium concentrations were measured using a fully
validated liquid chromatography–tandem mass spectrome-
try (LC–MS/MS) method with a lower limit of quantitation
(LLQ) of 0.04 ng/mL and 25 ng/mL, respectively. Plasma
and urine metformin concentrations were measured using a
validated LC–MS/MS method with an LLQ of 10 ng/mL
and 1 lg/mL, respectively.
2.2 Safety and Tolerability Evaluation
Adverse events (AEs) were recorded throughout the study
period. Clinical laboratory evaluations (haematology,
biochemistry and urinalysis) were performed at screening
and at the final day of the two treatment periods (Day 21
for Group A and Day 14 for Group B). Vital signs (heart
rate, blood pressure, respiration rate and oral body tem-
perature) were measured and 12-lead standard electro-
cardiograms (ECGs) performed at screening, the final day
of the two treatment periods (Day 21 for Group A and
Day 14 for Group B), and at the final study exit (Day 35).
Physical examinations were performed at screening, Day
8 (Group A) and Day 24 (Group B), and study exit (Day
35). Body weight was measured at screening and study
exit (Day 35).
2.3 Statistical Methods
2.3.1 Sample Size Calculation
The sample size required to power the study of steady-state
bioequivalence between trospium chloride XR and met-
formin was driven by within-subject variability as mea-
sured by the coefficient of variation for trospium chloride
XR (40 %). With a sample size of 18 in each sequence
(total of 36 subjects), a crossover design would yield 80 %
power to reject both the null hypothesis that the ratio of the
test mean to the standard mean is \0.80 and the null
hypothesis that the ratio of the test mean to the standard
mean is [1.25 (i.e., the test and the standard are not bio-
equivalent), in favour of the alternative hypothesis that the
means of the two treatments are bioequivalent. Accounting
for a 15 % drop-out rate, it was anticipated that approxi-
mately 44 subjects would need to be enrolled into the study
in order to have 36 subjects complete the study.
2.3.2 Pharmacokinetic Analyses
The calculation of pharmacokinetic parameters was per-
formed using WinNonlin Enterprise Version 5.2 with
IVIVC Toolkit (Pharsight Corporation, Mountain View,
CA, USA) and SAS for Windows Version 9.1 (SAS
Institute, Inc., Cary, NC, USA). The summary statistics of
the pharmacokinetic parameters were calculated using
SAS. SAS was also used for data management and other
Fig. 1 Study design. Asterisks denote visits involving an overnight stay at clinic. bid twice daily, qd once daily, XR extended release
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statistical analyses. S-Plus 7.0 (TIBCO Software, Inc.,
Seattle, WA, USA, formerly Insightful Corporation) was
used for the graphing of pharmacokinetic data.
Plasma: Trospium and Metformin A model-independent
approach was used to calculate the plasma and urine
pharmacokinetic parameters of trospium and metformin for
each subject. Plasma pharmacokinetic parameters, includ-
ing steady-state area under the plasma concentration–time
curve (AUC) within the dosing interval (AUC from time
zero to 12 hours [AUC12] for metformin and AUC from
time zero to 24 hours [AUC24] for trospium), maximum
(peak) drug concentration (Cmax), time to peak plasma
concentration (tmax) following drug administration, oral
clearance and half-life, were calculated when applicable.
Descriptive statistics were determined for all pharmacoki-
netic parameters calculated.
Pharmacokinetic DDIs were evaluated by calculating
the 90 % confidence interval (CI) of the ratio of estimated
geometric means for plasma AUC12 (metformin), AUC24
(trospium) and Cmax values obtained following adminis-
tration, alone and in combination. Administration alone
was used as the reference for each respective drug.
Urine: Trospium and Metformin The cumulative amount
of unchanged drug excreted in the urine (Ae) during the 12-
or 24-h dosing interval (Ae from time zero to 12 hours for
metformin and Ae from time zero to 24 hours for trospium)
was calculated for each subject. The percentage of dose
excreted in urine was determined from the ratio of Ae to the
administered dose. Renal clearance of drug from plasma
(CLR) was determined by dividing Ae by the plasma AUC
of the corresponding dosing interval of each drug. A paired
Student’s t test was performed to compare these parameters
between administration alone and in combination for each
compound at the significance level of 0.05.
2.3.3 Safety Analyses
All randomized subjects who received at least one dose of
study medication were included in the safety analyses. AE
data were summarized by frequency tables. Summary sta-
tistics were calculated with SAS for the change from
baseline in laboratory parameters, ECG parameters and
vital signs.
2.3.4 Post hoc Efficacy Analysis
To determine the clinical implications of the reduced
trospium exposure during concomitant metformin admin-
istration, a post hoc analysis was performed on efficacy
data reported from two multicentre, randomized, double-
blind, placebo-controlled Phase III trials [25, 26].
Comparison of primary efficacy outcomes (average number
of toilet voids and urinary urge incontinence [UUI] epi-
sodes per day) was conducted between subjects who
received both metformin and trospium chloride XR, and an
equal number of subjects not on metformin but who
received trospium chloride XR only (i.e., 1:1 matching).
Sensitivity analyses were also performed using twice the
number of control subjects (i.e., 1:2 matching). Addition-
ally, primary efficacy outcomes were compared between
subjects on metformin and all subjects who did not receive
metformin treatment (without matching). Control subjects
were selected by propensity score matching [27], with
propensity scores estimated using logistic regression with
metformin (yes vs. no) as a dependent variable, and age,
sex, race, OAB duration (years), baseline urinary fre-
quency, baseline urgency severity and baseline UUI epi-
sodes per day as independent variables.
2.4 Ethics
The study was conducted in accordance with the applicable
Good Clinical Practice regulations and guidelines and
Institutional Review Board (IRB) regulations. The study
was approved by Aspire IRB, La Mesa, CA, USA on 16
September 2009. All subjects provided written informed
consent prior to enrollment.
3 Results
A total of 44 subjects (25 males and 19 females) were
randomized to receive study treatment. Of these, 43 sub-
jects completed the study and one subject in Group B
discontinued at Day 13 due to flu-like symptoms consid-
ered unrelated to the study drug during the H1N1 pandemic
of 2009. The mean age was 31 years (range 18–44 years),
mean height was 165 cm (range 153–180 cm), and mean




The steady-state plasma concentration–time profiles of
metformin following administration of metformin alone
and in combination with trospium chloride XR are shown
in Figure 2. Coadministration of trospium chloride XR did
not alter the steady-state plasma and urine pharmacoki-
netics of metformin (Table 1). Based on the metformin
steady-state Cmax and AUC12 values, administration of
metformin alone and in combination with trospium chlo-
ride XR were bioequivalent; the 90 % CIs for the ratios of
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combination/alone were 97–109 (percentage ratio of the
geometric mean = 103) for Cmax and 105–120 (percent-
age ratio of the geometric mean = 112) for AUC12
(Table 1).
Following administration of metformin alone and in
combination with trospium chloride XR, comparable mean
values were observed for the CLR of metformin (33.0 and
33.7 L/h, respectively; p = 0.41) and the percentage of
dose excreted in urine (28.3 % and 31.9 %, respectively),
although the increase of approximately 13 % in percentage
of dose excreted in urine was statistically significant
(p \ 0.05; Table 1).
3.1.2 Trospium Chloride Extended Release
The steady-state plasma concentration–time profiles of
trospium following administration of trospium chloride XR
alone and in combination with metformin are shown in
Figure 3. Coadministration of metformin did not alter the
absorption rate of trospium from trospium chloride XR,
with tmax being approximately 4 hours for trospium chlo-
ride XR, both alone and in combination with metformin
(Table 2).
Administration of trospium chloride XR with metfor-
min, compared with trospium chloride XR alone, reduced
the trospium steady-state Cmax and AUC24 values by
approximately 34 % and 29 %, respectively (Table 2).
Although the percentage of trospium chloride XR dose
excreted in urine was reduced by 30 % (p \ 0.0001), there
was no statistically significant change in the CLR of tros-
pium when the drugs were coadministered (p = 0.88;
Table 2). Based on the trospium steady-state Cmax and
AUC24 values, administration of trospium chloride XR
alone and in combination with metformin resulted in 90 %
CIs for the ratios of geometric mean (combination/alone)
of 61–72 (percentage ratio of the geometric mean = 66.3)
for Cmax and 66–76 (percentage ratio of the geometric
mean = 70.8) for AUC24 (Table 2).
3.2 Safety and Tolerability
There were no serious AEs reported during this study, and
no subject discontinued the study due to an AE. A total of
97 treatment-emergent AEs (TEAEs) were reported by 26
subjects (59 %); these occurred in 11 subjects (26 %; 43
TEAEs) following administration of metformin alone,
eight subjects (18 %; 15 TEAEs) following administration
Fig. 2 Steady-state plasma concentration–time profiles of metformin
following oral administration of metformin 500 mg twice daily alone
and in combination with trospium chloride XR 60 mg once daily
(mean ± standard deviation, n = 43). XR extended release
Fig. 3 Steady-state plasma concentration–time profiles of trospium
following oral administration of trospium chloride XR 60 mg once
daily alone and in combination with metformin 500 mg twice daily
(mean ± standard deviation, n = 43). XR extended release
Table 1 Steady-state plasma and urine pharmacokinetic parameters
of metformin following oral administration of metformin 500 mg
twice daily, alone and in combination with trospium chloride XR







chloride XR (n = 43)
Cmax (ng/mL) 739 ± 263 753 ± 252
tmax (h) 1.39 ± 1.04 1.82 ± 1.10
AUC12 (ngh/mL) 4,450 ± 1,590 4,900 ± 1,550
t (h) 7.14 ± 3.37 5.73 ± 1.62
CLss/F (L/h) 127 ± 46 110 ± 27
Ae,12 (mg) 141 ± 50 160 ± 44
Ae,12/dose (%) 28.3 ± 10.0 31.9 ± 8.8
CLR (L/h) 33.0 ± 8.5 33.7 ± 8.5
Ae,12 cumulative amount of drug excreted in the urine from time zero
to 12 hours, AUC12 area under the plasma concentration–time curve
from time zero to 12 hours, CI confidence interval, CLR renal clear-
ance of drug from plasma, CLSS/F steady-state apparent body clear-
ance of drug from plasma after oral administration, Cmax maximum
(peak) plasma drug concentration, t terminal elimination half-life,
tmax time to reach maximum (peak) plasma concentration following
drug administration, XR extended release
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of trospium chloride XR alone, and 17 subjects (39 %; 39
TEAEs) following administration of trospium chloride XR
in combination with metformin. The most common TEAEs
were headache and diarrhoea (Table 3). Of the 97 TEAEs, 95
were mild in severity and two were moderate (headache).
Mean laboratory, vital sign and ECG parameters
remained within reference range at all assessed post-dose
time points and varied minimally from baseline. At
baseline, the mean heart rate was 69 beats/min (range
45–92 beats/min). On Day 1 of treatment, the mean change
in heart rate from baseline in Group A (metformin) and
Group B (trospium chloride XR ? metformin) was ?4.9
and ?3.4 beats/min, respectively, when measured 2 h post-
dose. In Group B, the mean change in heart rate from
baseline on Day 11 was ?6.1 beats/min when measured
immediately before dosing (pre-dose), and ?13.1 beats/
min when measured 2 h post-dose. Similarly, on Day 14
the mean pre-dose and post-dose changes in heart rate in
Group B were ?5.1 and ?8.8 beats/min, respectively.
There were no post-dose abnormal physical examination
findings. Mean weight from baseline to study exit increased
by 0.07 kg for Group A and 0.56 kg for Group B.
3.3 Post hoc Efficacy Analysis
Post hoc efficacy analyses from the pivotal Phase III
studies revealed that no statistical difference on the primary
efficacy outcomes at Week 12 (average number of toilet
voids/day or average number of UUI episodes/day) was
observed between patients on concomitant metformin and
trospium chloride XR therapy, and propensity score-mat-
ched trospium chloride XR patients who were not on
metformin therapy (Table 4).
4 Discussion
The primary finding of this DDI study is that the steady-
state pharmacokinetics of metformin were not affected by
Table 2 Steady-state plasma and urine pharmacokinetic parameters
of trospium following oral administration of trospium chloride XR
60 mg once daily, alone and in combination with metformin 500 mg











Cmax (ng/mL) 1.87 ± 1.44 1.17 ± 0.71
tmax (h) 4.42 ± 1.94 4.12 ± 1.60
AUC24 (ngh/mL) 22.7 ± 14.4 15.6 ± 9.5
CLss/F (L/h) 3,510 ± 1,920 4,830 ± 2,320
Ae,24 (mg) 0.400 ± 0.247 0.281 ± 0.156
Ae,24/dose (%) 0.667 ± 0.411 0.468 ± 0.260
CLR (L/h) 18.4 ± 4.8 18.4 ± 5.4
Ae,24 cumulative amount of drug excreted in the urine from time zero
to 24 hours, AUC24 area under the plasma concentration–time curve
from time zero to 24 hours, CI confidence interval, CLR renal clear-
ance of drug from plasma, CLSS/F steady-state apparent body clear-
ance of drug from plasma after oral administration, Cmax maximum
(peak) plasma drug concentration, tmax time to reach maximum (peak)
plasma concentration following drug administration, XR extended
release
Table 3 Treatment-emergent
adverse events occurring in
C5 % of subjects following oral
administration of metformin
alone, trospium chloride XR
alone, or metformin and













Headache 4 (9) 3 (7) 7 (16) 12 (27)
Diarrhoea 3 (7) 0 (0) 3 (7) 6 (14)
Abdominal distension 1 (2) 2 (5) 0 (0) 3 (7)
Abdominal pain, upper 3 (7) 0 (0) 0 (0) 3 (7)
Constipation 1 (2) 1 (2) 1 (2) 3 (7)
Dizziness 1 (2) 1 (2) 1 (2) 3 (7)
Dry throat 1 (2) 2 (5) 0 (0) 3 (7)
Nasal congestion 0 (0) 0 (0) 3 (7) 3 (7)
Abdominal pain 0 (0) 1 (2) 2 (5) 2 (5)
Dry lip 2 (5) 0 (0) 0 (0) 2 (5)
Metrorrhagia 2 (5) 0 (0) 0 (0) 2 (5)
Nausea 2 (5) 0 (0) 1 (2) 2 (5)
Oropharyngeal pain 0 (0) 1 (2) 1 (2) 2 (5)
Upper respiratory tract infection 0 (0) 0 (0) 2 (5) 2 (5)
Vomiting 1 (2) 0 (0) 1 (2) 2 (5)
White blood cells urine positive 1 (2) 1 (2) 0 (0) 2 (5)
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concomitant administration of trospium chloride XR in
healthy subjects. Notably, the CLR of metformin and
trospium was not changed significantly by coadministration
compared with administration of either drug alone.
It is important to evaluate whether any pharmacokinetic
DDI occurs between trospium and metformin, both of
which are eliminated via renal tubular secretion, as there is
considerable potential for these drugs to be concurrently
prescribed to patients with OAB. Metformin was the sixth
most commonly prescribed medication in the USA in 2009
[20], and it is the most widely prescribed oral treatment for
diabetes [21]. Metformin is indicated for the treatment of
type 2 diabetes, and may be used to prevent progression to
type 2 diabetes and to treat obesity. Diabetes (with type 2
diabetes accounting for 90 %–95 % of diabetes cases in
adults) [28] and obesity are highly prevalent in the USA
and worldwide; [29–32] furthermore, diabetes and obesity
are often co-morbid with OAB [3–6]. Among the pooled
population of patients enrolled in Phase III trospium
chloride XR studies, the mean body mass index (BMI) was
32 kg/m2, which exceeds the criterion used to define
obesity in adults (C30 kg/m2) [33]. A subanalysis of data
from these pivotal studies showed that the severity of OAB
increased with BMI; however, trospium chloride XR was
similarly efficacious, and significantly more effective than
placebo, across all BMI strata [33].
Trospium is primarily eliminated unchanged via renal
filtration and tubular secretion, rather than being metabo-
lized by CYP450. A theoretical DDI exists between tros-
pium and other renally eliminated drugs, such as metformin
[7], if there is competition between the agents for the same
transporter. Of note, a previous DDI study showed that
trospium chloride did not alter the pharmacokinetics of
digoxin, which is primarily eliminated by renal excretion
[10]. The current study expands on these findings, dem-
onstrating that trospium does not alter the pharmacokinet-
ics of metformin.
An interesting secondary finding of the present study
was the observation that coadministration of trospium
chloride XR with metformin resulted in reductions in the
mean steady-state Cmax (34 %) and AUC24 (29 %) of
trospium. On the surface, this observation suggests that
coadministration of metformin with trospium chloride XR
has the potential to interfere with the therapeutic efficacy
of the latter agent. However, this and other studies have
shown that there is very wide interindividual variability in
Table 4 Propensity score matching results: change from baseline at Week 12 in toilet voids and UUI episodes in subjects administered trospium
chloride XR with and without metformin [N or mean (SD)]
Characteristic Propensity score type
1:1 Matching 1:2 Matching
Metformin No metformin P value Metformin No metformin P value
Trospium chloride XR/placebo
N 78 78 78 156
Average no. of toilet voids/day -2.3 (2.7) -2.2 (3.3) 0.679a -2.3 (2.7) -2.0 (3.1) 0.243a
Average no. of UUI episodes/day -2.6 (3.6) -2.6 (4.1) 0.956a -2.6 (3.6) -2.4 (4.0) 0.547a
Trospium chloride XR
N 32 32 32 64
Average no. of toilet voids/day -3.2 (2.7) -2.5 (2.9) 0.195b -3.2 (2.7) -2.7 (2.9) 0.437b
Average no. of UUI episodes/day -3.1 (3.8) -2.6 (3.4) 0.294b -3.1 (3.8) -2.7 (3.4) 0.484b
Placebo
N 46 46 46 92
Average no. of toilet voids/day -1.7 (2.5) -1.7 (2.5) 0.944b -1.7 (2.5) -1.9 (3.1) 0.696b
Average no. of UUI episodes/day -2.3 (3.5) -2.2 (3.1) 0.722b -2.3 (3.5) -2.1 (3.0) 0.735b
No matching – – –
Placebo – – –
N 78 1,056 – – –
Average no. of toilet voids/day -2.3 (2.7) -2.3 (2.8) 0.979c – – –
Average no. of UUI episodes/day -2.6 (3.6) -2.1 (2.8) 0.338c – – –
a P values are based on Friedman test adjusting treatment group: trospium chloride XR vs placebo
b P values are based on Kruskal-Wallis test
c P values are based on rank analysis of variance model adjusting treatment group (trospium chloride XR vs placebo), age, race, baseline UUI
episodes per day
SD standard deviation, UUI urinary urge incontinence, XR extended release
Coadministration of Trospium Chloride XR and Metformin 129
trospium plasma levels after administration of trospium
chloride XR. For example, the mean AUC24 of trospium
was 20.2 ± 14.2 ngh/mL on Day 10 of administration in
another study of this formulation in healthy adult subjects,
which is intermediate between the mean values obtained
with and without concomitant metformin administration in
the present study [34]. Moreover, Silver et al. [34]
observed moderate to high (35 %–90 %) intersubject var-
iability in their study, and estimated the peak-to-trough
ratio (Cmax/Cmin) to range from 2 to 13. The trospium
chloride XR formulation produced a lower Cmax than that
of the immediate-release (IR) formulation in a head-to-
head comparison in healthy subjects [34]. This marked
change in pharmacokinetics resulted in no significant
change in the efficacy of the XR formulation relative to the
IR formulation, but was associated with improved tolera-
bility. Finally, as demonstrated in the above post hoc
analysis of data from the Phase III trials, the efficacy of
trospium chloride XR was not affected by metformin
coadministration, suggesting that the lower exposure of
trospium exposure during metformin coadministration is
not clinically significant.
As noted above, a subanalysis of data from Phase III
trials of trospium chloride XR showed that the efficacy of
the drug was consistent across BMI strata. Although the
study by Chancellor et al. [33] did not evaluate the impact
of metformin coadministration on the efficacy of trospium
chloride XR, the finding that efficacy was not impaired in
obese patients, who would be expected to be more likely to
be receiving antidiabetic agents, is reassuring.
Both metformin and trospium are substrates of the
proximal gut cation transporter system [23, 24]. Our
hypothesis is that metformin has a higher affinity/efficiency
of absorption compared with trospium chloride and,
therefore, competition between metformin and trospium for
the transporter limits absorption of trospium from the
intestine when the two drugs are coadministered. Appar-
ently, this competition did not take place in the renal
secretion process, as the renal clearance of trospium was
not affected. This might explain the observation in the
current study that trospium plasma concentration decreases
while clearance and dosing are unchanged. This hypothesis
will need to be specifically tested and confirmed via an
in vitro cellular culture model in which the OCT system is
expressed.
A potential limitation of the current study, as is typical
of pharmacokinetic studies, is that it was conducted in
healthy subjects with normal renal function; therefore, the
results observed in the study subjects may not be repre-
sentative of those that would be observed in patients with
co-morbid medical conditions that would necessitate con-
comitant prescribing of these medications. However, it
should be noted that because both drugs are eliminated
renally, neither metformin nor trospium chloride XR are
recommended for use in patients with severe renal
impairment (trospium chloride XR is not recommended for
use in patients with a creatinine clearance \30 mL/min;
metformin is contraindicated in patients with a serum
creatinine concentration C1.5 mg/dL [men] or C1.4 mg/dL
[women] or an abnormal creatinine clearance) [7, 11].
5 Conclusion
Coadministration of trospium chloride XR 60 mg once
daily and metformin 500 mg twice daily did not affect
the steady-state pharmacokinetics of metformin. There-
fore, no dosage adjustment is necessary for metformin
when it is coadministered with trospium chloride XR.
Coadministration of metformin reduced the steady-state
systemic exposure of trospium; however, renal clearance
of trospium remained unchanged. As this study was
conducted in healthy adult subjects, the results may not
be generalizable to patients with OAB in a clinical
setting.
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